{"id":"flucon","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":{"setId":"13184b13-e252-4b4d-a3e2-cfc4ad3d55b7","title":"FLUCONAZOLE TABLET [MAJOR PHARMACEUTICALS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the conversion of lanosterol to ergosterol, FLUCON® compromises the structural integrity and permeability of the fungal cell membrane, leading to cell death or growth inhibition. This mechanism is selective for fungal cells because they rely on ergosterol for membrane function, whereas mammalian cells use cholesterol instead.","oneSentence":"FLUCON® is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:30:16.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Candidiasis (oropharyngeal, esophageal, and systemic)"},{"name":"Cryptococcal meningitis"},{"name":"Other fungal infections (Aspergillus, Coccidioides, and other susceptible fungi)"}]},"trialDetails":[{"nctId":"NCT06209879","phase":"PHASE4","title":"Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-02-05","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT04117698","phase":"PHASE3","title":"Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-01","conditions":"Uveitis, Anterior","enrollment":116},{"nctId":"NCT02051023","phase":"PHASE3","title":"Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2014-02","conditions":"Dry Eye","enrollment":41},{"nctId":"NCT00824811","phase":"PHASE2","title":"Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Epiphora","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluorometholone"],"phase":"marketed","status":"active","brandName":"FLUCON®","genericName":"FLUCON®","companyName":"Military Hospital of Tunis","companyId":"military-hospital-of-tunis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FLUCON® is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, and systemic), Cryptococcal meningitis, Other fungal infections (Aspergillus, Coccidioides, and other susceptible fungi).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}